[이코노믹리뷰=황진중 기자] Huzel (145020), a global total medical esthetic company, announced that it will participate in the ’39th JP Morgan Healthcare Conference (JPMHC)’, which is held online from the 11th to the 14th (local time). Sun said.
Huzel, who participated in the JPMorgan Healthcare Conference as a presenter for the second consecutive year, announced ‘2020 achievements and vision for 2025′ through the’Emerging Market’ track on the 13th at 9:30 pm (Korean time). Meanwhile, during the conference period, one-on-one meetings with major overseas institutional investors will be held. The presentation will be attended by major executives and staff members including CEO Ji-hoon Son, Vice President of Development Division Chang-jin Lee, and Ji-hye Noh, Executive Vice President of Communication Division.
Huzel was the first in Korea and the fourth in the world to obtain an item license for the botulinum toxin drug’Letybo’ from China, drawing attention from the public, and being recognized for the company’s remarkable growth potential, the presenter once again following last year. I came out with it.
On this day, Huzel not only maintains its steadfast No. 1 position in the domestic market, but also introduces the competitiveness of a company that has emerged as a global key player as it succeeded in entering the Chinese market. It also discloses the vision for 2025 and the three-year growth strategy from 2021 to 2023 to achieve it.
This year, we plan to focus on the global business vision as we are planning to focus on the global business vision as we are preparing to enter the big market such as obtaining a license to sell botulinum toxin in Europe and submitting a BLA in the US. I plan to announce.
The blueprint for becoming a global leader in medical aesthetics is also released. As the world’s first company capable of manufacturing and selling all three items of botulinum toxin, HA filler, and lifting thread, the company explains its vision for growth through various R&D pipelines, open innovation strategies, and expansion of production facilities.
An official from Huzel said, “At the JP Morgan Healthcare Conference last year, we announced bold plans such as submitting a Chinese permit and BLA in Europe, and we are pleased to be invited as a presenter once again as we achieve this.” “Based on reliable product capabilities, “We will actively inform the market of Huzel’s corporate value and the company’s willingness and growth potential to become a global player.”